TakahiroIgnacioNakamuraMD

PubMed

• 18 citations
  Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
  Jordan E Axelrad, Terry Li, Salam P Bachour, Takahiro I Nakamura, Ravi Shah
  Inflammatory Bowel Diseases. 2023-06-01
• 11 citations
  SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
  Yoshihiro Kamada, Takahiro Nakamura, Satoko Isobe, Kumiko Hosono, Yukiko Suama
  Journal of Gastroenterology. 2023-02-01
• 12 citations
  Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
  Salam P Bachour, Ravi S Shah, Ruishen Lyu, Takahiro Nakamura, Michael Shen
  Clinical Gastroenterology and Hepatology. 2022-10-01

Journal Articles

• Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study  
  Wang J, Nakamura TI, Tuskey A, Behm B, Intestinal Research, 10/14/2019

Abstracts/Posters

• Tumor necrosis factor antagonists are superior to ustekinumab and vedolizumab for the prevention of postoperative recurrence in adult Crohn’s disease.
  Nakamura TI, Main M, Chang S, Click B, Hudesman DP, Axelrad JE., 2019 American College of Gastroenterology Annual Meeting, San Antonio, TX, 10/27/2019
• Polypharmacy and drug-drug interactions among patients with ulcerative colitis
  Figueroa E, Overby M, Behm B, Nakamura T, Wentworth B, American Journal of Gastroenterology, 114: S25-S26, 7/2019
• RISK FACTORS FOR NON-ADHERENCE TO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
  Brian J. Wentworth, Ross C.D. Buerlein, Takahiro I. Nakamura, Anne G. Tuskey, M. Ashely Overby, Mark E. Smolkin, Brian W. Behm, Gastroenterology, 1/2018